# Eikon Therapeutics, Inc. (EIKN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $8.52 (+1.91%)

> Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company pioneering advanced drug discovery through visualization of protein motion in living cells. Founded in 2019 and headquartered in Millbrae, California, it employs 384 people and focuses on developing therapies primarily for cancer treatment using innovative imaging techniques. The company integrates cutting-edge technology to observe dynamic protein behaviors, aiming to revolutionize how drugs are identified and optimized for oncology indications. Key leadership includes CEO Roger Perlmutter, co-founders Xavier Darzacq, Robert Tjian, and Eric Betzig, alongside experts like Chief Scientific Officer Dan Anderson and Chief Medical Officer Roy Baynes. Supported by prominent investors such as T. Rowe Price, Lux Capital, General Catalyst, and Foresite Capital, Eikon Therapeutics has raised substantial funding through multiple rounds, including a $351 million Series B in 2025. Operating in the biological products sector, it plays a significant role in advancing precision medicine for challenging diseases.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/EIKN)